Proteomic profiling in anti-VEGF-treated AMD patients reveals VEGF-independent immune pathway activation.
Why Immune Cells Keep Damaging Your Eyes
This observational study analyzed vitreous proteomic profiles in eight patients with neovascular AMD receiving anti-VEGF therapy compared to…
Standard eye drops for AMD stop one problem, but a second, hidden immune attack is still hurting your vision.
Biological DMARDs show marginal patient-reported outcome benefits over conventional therapy in early rheumatoid arthritis
Early rheumatoid arthritis patients report similar symptom relief with different treatment approaches
This open-label randomized trial in 795 newly diagnosed, DMARD-naïve RA patients compared three biological DMARDs plus methotrexate against …
In early rheumatoid arthritis, patients reported similar pain relief and quality-of-life improvements whether they started with conventional…
Post-hoc analysis of RCTs and cohorts identifies predictors of remission in ACPA-positive early RA treated with abatacept plus methotrexate or methotrexate alone.
Early disease activity and response predict remission in ACPA-positive rheumatoid arthritis patients
This post-hoc analysis of randomized controlled trials and an observational cohort evaluated predictors of DAS28-CRP remission in ACPA-posit…
Only early disease activity and treatment response predict remission in ACPA-positive rheumatoid arthritis, while genetic markers and imagin…
Phase 2 Study Evaluates Abatacept for Kidney Transplant Recipients
Could a new biomarker improve kidney transplant outcomes for patients?
A Phase 2 study is recruiting 800 kidney transplant recipients to assess HLA-DR/DQ mMM scores as prognostic biomarkers. A nested RCT will ev…
A new kidney transplant biomarker could predict complications, while a follow-up trial tests if switching to abatacept improves function and…